The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Image: Gilead’s John Milligan. Getty
Everybody in biopharma talks about unmet medical needs when they review their late-stage pipeline, but it’s the market potential that will either whip up investors or leave them cold about any innovation. The top 10 prospective drug launches looming in 2018 — as selected by Evaluate in its 2018 preview — underscores all the potential of the would-be blockbusters that always dominate biopharma R&D news.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.